Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Pharmaceuticals Industry
Nov 21, 2008 04:22 PM
- Biogen Reports Another PML Case in Tysabri Patient
Oct 30, 2008 01:24 AM
- Biogen Significantly Undervalued - Analyst Blog
Oct 22, 2008 02:28 PM
- Earnings Results Analysis – 21 Oct
Oct 21, 2008 03:24 PM
- Biogen Idec Upgraded to a Buy
Oct 13, 2008 12:25 PM
- Glancing at the Health Care Sector XLV
Aug 21, 2008 03:35 AM
- Financials' Share of Earnings Plunges More
Aug 19, 2008 01:39 PM
- Institutional Money Flocking in Biotech
Aug 15, 2008 01:23 PM
- Analyst Comments: Chunghwa Telecom, PG&E Corporation, Valspar, Estee Lauder, PALM, GameStop, Kinross Gold, Denbury Resources, Aegon, Biogen Idec, General Dynamics
Aug 15, 2008 09:12 AM
- Genentech rejects Roche Buyout, Shares keep climbing
Aug 13, 2008 01:10 PM
- Health Care Poised to Weather Recession
Nov 02, 2008 10:54 AM
- Health care, defense poised to weather recession
Nov 01, 2008 01:54 PM
- Stocks Recover, but Finish Lower
Oct 13, 2008 11:16 AM
- Movers: Goldman Sachs, Morgan Stanley, Citigroup, Wachovia, Wells Fargo, GE
Oct 13, 2008 10:55 AM
- Stocks Keep Spiraling Down
Oct 08, 2008 11:01 AM
- Movers: Bank of America, Morgan Stanley, Royal Bank of Scotland, AMD
Oct 08, 2008 10:52 AM
- Conseco, OfficeMax, Goldman Sachs among big movers
Sep 19, 2008 04:14 PM
- Analyst Actions: Elan, Sun Microsystems, VistaPrint
Aug 04, 2008 10:54 AM
- Movers: GM, Ambac, Lehman Brothers, Chevron, Biogen, Elan, Cigna
Aug 04, 2008 10:53 AM
- Biogen Idec to Present at the Lazard Capital Markets Fifth Annual Life Sciences Conference
Nov 14, 2008 02:38 PM
- Biogen Idec to Present at the Credit Suisse 2008 Healthcare Conference
Nov 07, 2008 02:25 PM
- Biogen Idec Elects to Participate with Genentech in the Development and Commercialization of a Next Generation Anti-CD20 Molecule
Oct 30, 2008 04:06 PM
- Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: CPO, CHH, PHM, BIIB, AVP, SLAB
Oct 29, 2008 12:16 PM
- Rituxan Data in Patients with Rheumatoid Arthritis to Be Presented at the American College of Rheumatology Annual Scientific Meeting
Oct 27, 2008 09:21 AM
- Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis
Oct 23, 2008 06:31 PM
- Biogen Idec Reports Third Quarter 2008 Results
Oct 21, 2008 07:15 AM
- Biogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid Arthritis
Oct 09, 2008 04:03 PM
- Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia
Oct 07, 2008 01:31 AM
- Biogen Idec to Report Third Quarter 2008 Financial Results on October 21, 2008
Sep 30, 2008 05:03 PM
- Form 4 BIOGEN IDEC INC. For: Nov 06 Filed by: HASLER HANS PETER (10K)
Nov 07, 2008 03:02 PM
- Form 4 BIOGEN IDEC INC. For: Nov 06 Filed by: Hamm Robert A (10K)
Nov 07, 2008 02:59 PM
- Form 4 BIOGEN IDEC INC. For: Nov 01 Filed by: Hamm Robert A (10K)
Nov 04, 2008 02:58 PM
- Form 4 BIOGEN IDEC INC. For: Nov 01 Filed by: HASLER HANS PETER (10K)
Nov 04, 2008 02:58 PM
- Form 4 BIOGEN IDEC INC. For: Nov 01 Filed by: MacLean Michael F (10K)
Nov 04, 2008 02:58 PM
- Form 4 BIOGEN IDEC INC. For: Oct 06 Filed by: MacLean Michael F (10K)
Oct 06, 2008 06:31 PM
- Form 4 BIOGEN IDEC INC. For: Oct 02 Filed by: PICKETT CECIL B (10K)
Oct 06, 2008 10:43 AM
- Form 4 WIGGINS MARK C For: Sep 26 (10K)
Sep 29, 2008 04:44 PM
- Form 4 BIOGEN IDEC INC. For: Sep 19 Filed by: Clancy Paul J (10K)
Sep 23, 2008 12:01 PM
- Form 4 BIOGEN IDEC INC. For: Sep 04 Filed by: Clancy Paul J (10K)
Sep 08, 2008 12:30 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
BIIB
|
Compare to S&P
|
| YTD |
-25.67 %
|
21.78 %
|
| 4 Weeks |
-0.56 %
|
7.48 %
|
| 12 Weeks |
-12.92 %
|
20.70 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 4.40 %
|
|
EPS Growth in Last Year: 72.73 %
|
|
Sales Growth in Last Quarter: 10.02 %
|
|
Sales Growth in Last Quarter: 38.48 %
|
|
|
